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Abstract: l-Carnosine (β-Ala-l-His) and several other histidine-containing peptides, including two
N-methylated forms on the imidazole ring (l-anserine and l-balenine), two derivatives modified on
the carboxyl function (carcinine and l-carnosinamide), two analogues differing in the length of the
N-terminal residue (l-homocarnosine and Gly-l-His) and the N-acetyl derivatives, were investigated
as activators of four isoforms of the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1). The four
human isoforms hCA I, II, VA and IX were activated in the low to high micromolar range, with
a rather complex structure activity relationship. A performed computational study allowed us to
rationalize these results and to propose a binding mode of these activators within the enzyme active
site. Similarly to other CA activators, the here studied peptides could find relevant pharmacological
applications such as in the management of CA deficiencies, for therapy memory and enhancing
cognition or for artificial tissues engineering.
Keywords: carbonic anhydrase; activator; proton shuttling; carnosine; histidine; dipeptide
1. Introduction
The dipeptide l-carnosine (β-Ala-l-His) represents the prototype of a set of histidine-containing
peptides which are found in the entire animal kingdom, where they are primarily expressed in the
muscles and are significantly abundant also in other excitable tissues [1,2]. As shown in Table 1, they
include two N-methylated forms on the imidazole ring (l-anserine and l-balenine), two derivatives
modified on the carboxyl function (carcinine and l-carnosinamide), two analogues differing in the
length of the N-terminal residue (l-homocarnosine and Gly-l-His) and the N-acetyl derivative [3,4].
The detailed physiological and biochemical roles of these derivatives are still to be completely clarified,
even though some bioactivities can be argued from their physicochemical properties. Thus, the
well-known properties of the imidazole ring render almost all these derivatives metal-chelators,
antioxidants and endowed with a significant buffering capacity [5]. Apart from N-acetyl-l-carnosine,
these dipeptides are also able to inhibit the protein carbonylation by quenching reactive carbonyl species
(RCS) through a two-steps mechanism which involves both the primary amine and the imidazole ring
and yields a final Michael adduct [6]. The buffering capacity is primarily ascribable to the ionization
properties of the imidazole ring which shows a pK value (pK = 6.72) close to the physiological pH [7].
However and along with this clear and direct mechanism, also indirect mechanisms can contribute
to the buffering capacity especially when considering that histidine analogues (such as histamine
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and histidine itself [8]) are reported to be potent activators of some isoforms of the human carbonic
anhydrases (hCAs) which play a key role in modulating and maintaining the physiological pH [9]:
EZn2+OH− + CO2 
 EZn2+HCO3−
+H2O
 EZn2+OH2 + HCO3− (1)
EZn2+OH2 
 EZn2+OH− + H+ (rate determining step) (2)
In the presence of an activator molecule ‘A’, Equation (2) becomes (3), as in the enzyme-activator
complex the proton transfer reaction is no longer intermolecular but intramolecular, and thus
favored [3,10]:
EZn2+OH2 + A 

[
EZn2+OH2+A
]


[
EZn2+HO−AH+
]

 EZn2+HO− + AH+
enzyme-activator complexes
(3)
The interest for CAs activators has remarkably increased [10–13] in the last few years since the CA
activation mechanism has been elucidated by one of our groups [8]. Indeed, CA activators (CAAs)
participate to the catalytic cycle (Equations (1) and (2) above), more exactly in the rate determining step
of it, which consists in the formation of the zinc hydroxide species of the enzyme by the loss of a proton
from an acidic enzyme species, which has the zinc ion coordinated by three His residues and a water
molecule, as shown in Equation (2) [8,11]. The proton is transferred from the water molecule to the
external medium, and in many CA isoforms this process is assisted by residue His64, the proton shuttle
residue, located in the middle of the active site cavity [8,10–13]. In the presence of CAAs, the proton
transfer is performed both through the canonical, His64 shuttling, and through and additional shuttling
which involves the activator molecule, which generally possesses protonatable moieties with pKa
values in the range of 6–8 [11]. This is achieved through the formation of enzyme-activator complexes,
as shown above in Equation (3), in which the proton transfer is intramolecular (nor intermolecular as
in Equation (2), and as thus, favored [8,10–13].
The first study reporting the l-carnosine effect on the hCA enzymatic activity dates back to 2002
when a set of derivatives incorporating arylsulfonylureido moieties were described as potent and
selective hCA activators [14]. Since then, very few studies have investigated the role of the carnosine
derivatives on hCA enzymes and all these studies were focused on synthetic compounds as exemplified
by the halogenated analogues proposed by Saada et al. in 2014 [15], while the activity of the above
described set of natural histidine containing dipeptides was never investigated in a comprehensive way.
On these grounds, the present study was undertaken to systematically investigate the activating
profiles of these histidine containing derivatives on a panel of representative human CA isozymes
including hCA I, hCA II, hCA VA and hCA IX. As listed in Figure 1 and Table 1, the study comprised the
above mentioned naturally occurring carnosine derivatives, two analogues including the non-natural
D-His residue (i.e., d-carnosine [16] and d-carnosinamide), the tripeptide Gly-Gly-l-His, a well-known
metal chelator [17], chosen here to investigate the capacity of enzymatic binding cavity to accommodate
larger derivatives and finally a recently proposed synthetic analogue modified on the carboxyl group
(i.e., l-carnosinol) [18]. The monitored bioactivities were finally rationalized by docking simulations
involving the hCA II isozyme chosen due to the availability of resolved structures in complex with
histidine [19].
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KA (µM) * 
hCA I hCA II hCA VA hCA IX 
1 L-carnosine COOH H H 2 92.1 83.4 17.2 46.3 
2 D-carnosine COOH H H 2 54.3 76.6 8.93 10.1 
3 L-carnosinamide CONH2 H H 2 45.2 91.5 18.5 4.71 
4 D-carnosinamide CONH2 H H 2 16.6 >100 16.1 45.5 
5 L-homocarnosine COOH H H 3 77.0 88.9 51.3 7.35 
6 L-anserine COOH H 1-Me 2 80.4 93.7 17.4 1.14 
7 L-balenine COOH H 3-Me 2 20.7 >100 47.2 50.2 
8 carcinine H H H 2 16.6 >100 6.4 38.0 
7 Gly-L-His COOH H H 1 31.9 90.1 9.83 11.5 
8 Gly-Gly-L-His COOH Gly H 1 74.3 >100 52.8 19.4 
9 N-acetyl-L-carnosine COOH Acetyl H 2 79.6 102 47.1 32.6 
10 L-carnosinol CH2OH H H 2 28.3 >100 12.2 20.5 
11 histamine - - - - 2.1 125 0.010 35.1 
* Mean from three different assays (errors in the range of ± 10% of the reported values, data not shown). 
2. Results 
2.1. Biological Activity 
Table 1 reports the activation constants (KA) for the here analyzed histidine containing 
derivatives as obtained by a stopped-flow CO2 hydrase assay on hCA I, hCA II, hCA VA and hCA IX 
isozymes. For a facile comparison, Table 1 includes also the activation constants for the reference 
compound histamine. A first general consideration involves the KA averages for the four monitored 
CA isoforms (hCA I = 51.42 µM, hCA II = 93.85 µM, hCA VA = 25.41 µM and hCA IX = 23.94 µM) 
which reveal that the tested compounds showed an activation profile partly different compared to 
that of histamine. Indeed, histamine and carnosine analogues share a very modest activity on hCA 
II, while differing for the activity on the other three isozymes. In detail, histidine containing ligands 
show a good and similar activity on hCA VA and hCA IX and an overall poorer activity on hCA I, 
thus leading to a general activity trend, which can be schematized by: hCA IX ≅ hCA VA > hCA I >> 
hCA II. 
A comparative analysis between the compiled KA values reveals that there is no correlation 
between them (maximum r value equal to 0.48 between KA values of hCA II and hCA VA) and this 
finding is clearly evident when considering that the most active compounds vary in the monitored 
isoforms and are: D-carnosinamide for hCA I, D-carnosine for hCA II, carcinine for hCA VA, and L-
anserine for hCA IX which shows the best KA value. The lack of correlations underlines that the 
activity of these derivatives, while sharing a common activating mechanism, is influenced by 
isozyme-specific factors, a finding which is in line with the above discussed activity trend. 
A detailed analysis of the activity profiles for the tested compounds allows for some interesting 
considerations. First, D-carnosinamide, carnosinol and carcinine are more active on hCA VA 
compared to hCA IX, thus suggesting that modifications on the C-terminus, which neutralize the 
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Table 1. Considered carnosine derivatives 1–10 and their CA activating properties against human
CA isoforms hCA I, II, VA and IX, by a stopped-flow CO2 hydrase assay. Histamine 11 was used as
reference standard activator.
No. Compound R R1 X n
KA (µM) *
hCA I hCA II hCA VA hCA IX
1 l-carnosine COOH H H 2 92.1 83.4 17.2 46.3
2 d-carnosine COOH H H 2 54.3 76.6 8.93 10.1
3 l-carnosinamide CONH2 H H 2 45.2 91.5 18.5 4.71
4 d-carnosinamide CONH2 H H 2 16.6 >100 16.1 45.5
5 l-homocarnosine COOH H H 3 77.0 88.9 51.3 7.35
6 l-anserine COOH H 1-Me 2 80.4 93.7 17.4 1.14
7 l-balenine COOH H 3-Me 2 20.7 >100 47.2 50.2
8 carcinine H H H 2 16.6 >100 6.4 38.0
7 Gly-l-His COOH H H 1 31.9 90.1 9.83 11.5
8 Gly-Gly-l-His COOH Gly H 1 74.3 >100 52.8 19.4
9 N-acetyl-X-carnosine COOH Acetyl H 2 79.6 102 47.1 32.6
10 l-carnosinol CH2OH H H 2 28.3 >100 12.2 20.5
11 histamine - - - - 2.1 125 0.010 35.1
* Mean from three different assays (errors in the range of ± 10% of the reported values, data not shown).
2. Results
2.1. Biological Activity
Table 1 reports the activation constants (KA) for the here analyzed histidine containing derivatives
as obtained by a stopped-flow CO2 hydrase assay on hCA I, hCA II, hCA VA and hCA IX isozymes.
For a facile comparison, Table 1 includes also the activation constants for the reference compound
histamine. A first general consideration involves the KA averages for the four monitored CA isoforms
(hCA I = 51.42 µM, hCA II = 93.85 µM, hCA VA = 25.41 µM and hCA IX = 23.94 µM) which reveal
that the tested compounds showed an activation profile partly different compared to that of histamine.
Indeed, histamine and carnosine analogues share a very modest activity on hCA II, while differing
for the activity on the other three isozymes. In detail, histidine containing ligands show a good and
similar activity on hCA VA and hCA IX and an overall poorer activity on hCA I, thus leading to a
general activity trend, which can be schematized by: hCA IX  hCA VA > hCA I >> hCA II.
A comparative analysis between the compiled KA values reveals that there is no correlation
between them (maximum r value equal to 0.48 between KA values of hCA II and hCA VA) and this
finding is clearly evident when considering that the most active compounds vary in the monitored
isoforms and are: d-carnosinamide for hCA I, d-carnosine for hCA II, carcinine for hCA VA, and
l-anserine for hCA IX which shows the best KA value. The lack of correlations underlines that
the activity of these derivatives, while sharing a common activating mechanism, is influenced by
isozyme-specific factors, a finding which is in line with the above discussed activity trend.
A detailed analysis of the activity profiles for the tested compounds allows for some interesting
considerations. First, d-carnosinamide, carnosinol and carcinine are more active on hCA VA compared
to hCA IX, thus suggesting that modifications on the C-terminus, which neutralize the negative charge
of the carboxyl group, can promote the hCA VA activity. Second, l-homocarnosine, Gly-Gly-l-His and
N-acetyl-l-carnosine are more active on hCA IX compared to hCA VA, thus suggesting that increasing
the steric hindrance of the N-terminus favors the interaction with hCA IX. Thirdly and apart from
hCA II, for which all tested derivatives reveal very poor activities, the two methylated analogues (i.e.,
l-anserine and l-balenine) show very marked differences in all other isoforms although with different
trends, since l-balenine is the more active regioisomer in hCA I, while l-anserine is more active on
hCA VA and hCA IX. Such a remarkable regioselectivity emphasizes the pivotal role played by the
imidazole ring in enhancing the catalytic activity as rationalized by the following docking simulations.
Finally and with regard to the studied enantiomeric pairs, Table 1 shows that d-carnosine is more
active than l-carnosine in all tested isozymes with the hCA IX subtype being the most enantioselective
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one (ER = 4.6). As described by the following docking simulations, such an enantioselectivity can be
explained by considering that the imidazole ring has to assume a well-defined arrangement to promote
the enzymatic activity and this is clearly influenced by the histidine configuration. Based on these
premises and considering the remarkable activity of l-carnosinamide on hCA IX, the synthesis of the
d-carnosinamide was accomplished. Unfortunately, d-carnosinamide was found to be the eutomer on
hCA I, roughly equipotent on hCA II and hCA VA, but markedly less active than l-carnosinamide on
hCA IX (ER = 9.7). This unsatisfactory result can be rationalized by considering that the different steric
hindrance of the residues contacting the C-terminus between the tested isozymes can alter the relation
between activity and configuration as suggested by the following calculations.
2.2. Computational Study for the Binding of CAAs
With a view to rationalizing the activity profiles described above, docking simulations were
performed on the hCA II isoform. Even though the tested compounds show, on average, poor
activities on this isozyme, the availability of resolved structures in complex with structurally related
activators [19] allow the generation of reliable docking results, which can be utilized to extrapolate
general hints in order to explain the observed differences between the tested ligands in the other
isozymes. Figure 2A shows the putative complex for the most active d-carnosine within the CA II
catalytic cavity and reveals that the ligand’s imidazole ring assumes a pose superimposable with that
observed for the co-crystallized histidine and is surrounded by a set of interacting residues with which
it can elicit pi-pi stacking plus H-bonds (such as Asn62, His64, Asn67, Gln92 and, to minor extent His94).
The involvement of amide containing side chains seems to confirm the stabilizing role of stacking
interactions between amide and heteroaryl moieties as recently investigated [20].
The key differences between d-carnosine and the resolved histidine concern the arrangement of
the charged termini. Here, the carboxyl terminus is seen to contact Trp5 eliciting a weak H-bond,
while the β-alanine portion assumes a folded geometry by which it contacts hydrophobic residues
(Val135, Leu141, Pro202 and Leu204), with the ammonium head approaching Phe131 with which
it can stabilizes charge transfer interactions. Since the interactions described above involve almost
all d-carnosine moieties, one may explain the observed stereoselectivity between the two carnosine
enantiomers, especially when considering the steric hindrance exerted by Trp5. Indeed, Figure 2B
compares the best poses as computed for the two carnosine enantiomers and reveals that the charged
termini of l-carnosine assume a swapped pose by which its imidazole ring is constrained to assume a
more external arrangement compared to that seen for d-carnosine.
Overall, the described complexes are seen to tightly stabilize the arrangement of the imidazole ring,
which is directly involved in the activating mechanism, while the charged termini seem to be engaged
by weaker contacts and play a rather marginal role. This finding can explain why modifications on the
charged moieties often exert beneficial effects. The positive effect can be also due to the breaking of
the intramolecular ionic bridge, which negatively constrains the flexibility and the accommodation of
the beta-alanine residue. Without this, the N-terminal tail increases its flexibility and facilitates the
accommodation even of bulky derivatives as exemplified by N-acetyl-carnosine, which assumes more
extended conformations by which its N-terminal portion approaches the residues lining the cavity rim,
such as Trp5, Trp16, Phe20, Phe131, Val135, Pro202 and Leu204. Notably, Trp5 and more in general
the above mentioned residues can explain the different sensitivity to the ligand size as observed for
the considered isoforms. The greatest differences are observed in the first three residues since the
Trp-Trp-Phe triad of hCA II is replaced by a similarly bulky Trp-Trp-Tyr triad in hCA I and hCA VA,
while being clearly less bulky in hCA IX (Gly-Trp-Ser), thus justifying the good activity that bulky
ligands, such as Gly-Gly-His and homocarnosine, show for hCA IX. By contrast, the hydrophobic region
around Pro202 is highly conserved in all considered isozymes as depicted in the inlet of Figure 2A.
With a view to rationalizing the differences observed in the CA isozymes, the inlet in Figure 2A
displays the sequence alignments between the four considered CA subtypes focusing attention on the
residues primarily involved in the activator recognition. With regard to residues facing the imidazole
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ring, Figure 2A reveals that the residues Gln92, His94, His96, which are also involved in zinc chelation,
are constantly conserved in all subtypes, while greater differences are seen in the residues around
His64, which is conserved in all isoforms apart from CA VA where it is replaced by a tyrosine.
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Figure 2. Main interactions stabilizing the putative complexes as computed for d-carnosine (A) and
comparison between d-carnosine (in orange) and l-carnosine (in green) within the hCA II binding
site (B). In both Figures, the zinc ion plus the coordinating histidine residues are depicted in purple.
The inlet in Figure 2A shows the multiple sequence alignments (and the relative consensus) for the four
tested CA isoforms as computed by ClustalX [21].
In detail, Asn62 and Asn67 show a larger variability, which can explain the different regioselectivity
shown by the methylated analogues. Indeed, in all isozymes, hCA I excepted, anserine is more active
than balenine and all isoforms show H-bonding residues in those positions apart from CA I which
has an alkyl side chain (Val63), thus suggesting that the corresponding missed H-bond can induce
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the regioselectivity change observed in CA I. Ala 65 is replaced in hCA I and hCA IX by H-bonding
residues and this can beneficially contribute to their interaction with the tested activators.
3. Discussion
To the best of our knowledge, this is the first study which investigates in a comprehensive way
an extended set of naturally occurring histidine-containing peptides against a representative panel
of therapeutically relevant hCA isoforms. The obtained results highlight that, apart from the CA II
isoform, on which all imidazole derivatives show very poor activities, almost all tested molecules elicit
significant activating effects which appear to be more marked on the hCA VA and hCA IX isozymes.
As mentioned in the Introduction, various biological activities were reported for carnosine and its
derivatives [22] and the still debated mechanisms were substantially related to their chemical properties
and in particular to the specific characteristics of the imidazole ring which render such molecules
antioxidants, buffers, metal-chelators and carbonyl quenchers [23,24]. All reported therapeutic effects
were supposed to be an indirect consequence of the above cited chemical effects and until now very
few direct mechanisms based on the carnosine interaction with specific targets were reported [25].
In contrast, this study underlines that the histidine containing peptides are able to significantly
increase the activity of different carbonic anhydrases through a specific binding within their catalytic
pockets. On these grounds, one may consider that the observed capacity of carnosine analogues to
restore and maintain the physiological pH is not merely due to an intrinsic buffering capacity of the
imidazole ring, but is also ascribable to the catalytic effect on CA isoforms. Clearly, the relation between
buffering capacity and CA activation depends on the peptide concentration and the key relevance of
such an enzymatic mechanism is that it may occur at concentrations far below than those required
for a satisfactory buffering effect especially for the most active compounds. When considering the
rapid hydrolysis that carnosine and some of its derivatives undergo in plasma by serum carnosinase,
one may figure out that the buffering capacity has a predominant (but yet not exclusive) role in those
tissues which synthesize carnosine at mM concentrations (such as skeletal muscles) [26] while the CA
activation can have a relevant role in the other tissues which are reached by low (but non-negligible)
amounts of histidine containing peptides [27]. In this context, the carnosine analogues which show
a lower susceptibility to the carnosinase hydrolysis (such as homocarnosine and anserine) can have
crucial effects [28].
Remarkably, such an activation effect on CAs allows for a better understanding of many reported
carnosine biological activities. As an example, several studies reported significant beneficial effects
of carnosine and its analogues on cognitive impairment [29,30] and the proposed mechanisms were
substantially focused on antioxidant and metal-chelation properties of these peptides which elicit
anti-inflammatory and anti-aggregant neuroprotective effects. [31] Since the CA activators are emerging
for their capacity to enhance cognition and memory [10,11], the here reported results suggest that
the beneficial effects of histidine containing dipeptides on brain activity can be also ascribed to their
activating effects on CA isozymes.
4. Materials and Methods
4.1. Materials
l-Carnosine, d-carnosine and l-carnosinol were kindly provided by Flamma S.p.A. (Chignolo
D’Isola, Bergamo, Italy). l-Carnosinamide, l-homocarnosine, l-anserine, carcinine, Gly-l-His,
Gly-Gly-l-His and N-acetyl-l-carnosine were purchased from Merck KGaA (Darmstadt, Germany),
while l-balenine was prepared following a previously described procedure [32].
4.2. Synthesis of d-Carnosinamide
d-Carnosine (100.0 mg, 0.44 mmol) was dissolved in HCl/Et2O (1.3 N, 7.0 mL). The solution was
cooled at 5 ◦C and then SOCl2 (0.1 mL, 1.32 mmol) was added dropwise. Subsequently the mixture
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was allowed to reach room temperature and DMF (2 mL) was added. Then the reaction mixture was
heated at reflux overnight. Next, the mixture was cooled at 5 ◦C, saturated with NH3 and stirred
overnight (Scheme 1). Afterwards the solid was removed by filtration, washed with cooled Et2O (3 × 2
mL) and dried under vacuum to obtain d-carnosinamide as a hygroscopic white solid (74.34 mg; 75%
yield). H-NMR (300 MHz, D2O) δ (ppm): 7.48 (s; 1H); 6.68 (s; 1H); 4.38 (dd; 1H, X of His, JXA = 8.3 Hz,
JXB = 6.0 Hz); 3.01 (t; 2H, Hz CH2 α to the NH2, J = 6.7 Hz); 2.90 (dd; 1H; B of His, JAB = 15.0 Hz, JBX =
6.0 Hz, 1H); 2.91 (dd; 1H; A of His, JBA = 15.0, JAX 8.3 Hz); 2.45 (m; 2H, CH2 in β to NH2).
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4.3. Biological Assays
An Sx.18Mv-R Applied Photophysics (Oxford, UK) stopped-flow instrument has been used to
assay the catalytic activity of vari us CA isozymes for CO2 hydration reaction [33]. Ph nol red (at
concentration of 0.2 mM) was used as indicator, working at the absorbance maximum f 557 nm,
with 10 mM Hepes (pH 7.5, for α-CAs) or TRIS (pH 8.3, for γ-CAs) as buffers, 0.1 M NaClO4 (for
maintaining constant ionic strength), f llowing the CA-catalyzed CO2 hydration reaction for a period
of 10 s at 25 ◦C. The CO2 conce trations ranged from 1.7 to 17 mM for t e determin tion o the kinetic
parameters and inhibition constants. For each activator at least six traces of the initial 5–10% of the
reaction have bee used for determining the initial velocity. The uncatalyzed rates were determined
in the same manner and subtracted from the tot observed rates. Stock solutions of activators (at
0.1 mM) were prepared in distill -deioniz d water and dilutions up to 1 nM were made thereafter
with the assay buffer. Enzym and activator solutions were pre-incubated together for 15 min p ior o
assay, in order to allow for the formati n of the e zyme–activator complexes. The activatio constant
(KA), defined similarly with the inhibition constant KI, can be btained by consider ng the las ical
Michaelis–Menten equation (Equation (4)), which has been fitt d y non-linear least squares by u ng
PRISM 3:
v = vmax/{1 + (KM/[S])(1 + [A]f/KA)} (4)
where [A]f is the free concentration of activator.
Working at substrate concentrations considerably lower than KM ([S] << KM), and considering
that [A]f can be represented in the form of the total concentration of the enzyme ([E]t) and activator
([A]t), the obtained competitive steady-state equation for determining the activation constant is given
by Equation (5):
v = v0.KA/{KA + ([A]t − 0.5{([A]t + [E]t + KA) − ([A]t + [E]t + KA)2 − 4[A]t.[E]t)1/2}} (5)
where v0 represents the initial velocity of the enzyme-catalyzed reaction in the absence of activator [34–37].
4.4. Molecular Modelling
The conformational profile of the tested activators was explored as explained in previous
studies [38]. Even though the induced CA-II activation is very weak, docking simulations involved
this isoform due to the availability of resolved structures in complex with activators. Indeed and due
to the satisfactory degree of conservation of the residues involved in the activator’s binding site (see
Figure GV1C), these resolved CA-II complexes can be used as a general platform to rationalize the
obtained results for all the evaluated isoforms. In detail, docking simulations involved the resolved
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CA-II structure in complex with L-histidine (PDB Id: 2ABE), a known activator similar to those
here considered [17]. The CA structure was prepared by removing water molecules (apart from that
bound to zinc ion) and crystallization additives. After preliminary checks to avoid gaps or unphysical
occurrences, the enzyme structure was then minimized by keeping fixed backbone atoms plus zinc ion
and chelating residues to preserve the resolved folding. The so optimized CA-II structure was finally
used in docking simulations after removing the bound activator. In detail, docking calculations were
based on the PLANTS program and focused onto a 10 Å around the bound (and deleted) activator [39].
For each tested ligand, 10 poses were generated and scored by the ChemPLP function with a speed
equal to 1. Even without simulating explicitly the network of water molecules which connects the
activator to zinc ion and which is required for the activation mechanism, the generated poses were
also selected by considering the distance between the ligand’s imidazole ring and the zinc ion which
should fall around 7.5 Å as seen in the resolved structure.
5. Conclusions
In summary, the present study investigated the activating effects of an extended set of histidine
containing peptides on therapeutically relevant hCA isozymes revealing their significant activities on
all tested hCA subtypes apart from hCA II on which all histidine analogues are poorly active. SAR
analysis and docking simulations emphasize the key role of the imidazole ring as well as, to minor
extent, of the C-terminus, while the N-terminal residues appears to play a more marginal role affecting
at most the subtype-selectivity. The here reported activities allow for an in depth re-evaluation of many
biological activities ascribed to carnosine and its derivatives and, more generally, these compounds
appear to be valuable candidates for the various applications recently emerged for the CA activators,
such as in the management of CA deficiencies, for therapy memory and enhancing cognition and for
artificial tissues engineering based on bioinorganic scaffolds.
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